Arrowhead Pharmaceuticals (ARWR) Accumulated Depreciation & Amortization (2016 - 2025)
Historic Accumulated Depreciation & Amortization for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Q4 2025 value amounting to $6.0 million.
- Arrowhead Pharmaceuticals' Accumulated Depreciation & Amortization rose 2500.0% to $6.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $6.0 million, marking a year-over-year increase of 2500.0%. This contributed to the annual value of $22.2 million for FY2025, which is 3136.09% up from last year.
- Per Arrowhead Pharmaceuticals' latest filing, its Accumulated Depreciation & Amortization stood at $6.0 million for Q4 2025, which was up 2500.0% from $22.2 million recorded in Q3 2025.
- Arrowhead Pharmaceuticals' 5-year Accumulated Depreciation & Amortization high stood at $22.2 million for Q3 2025, and its period low was $1.5 million during Q1 2021.
- Over the past 5 years, Arrowhead Pharmaceuticals' median Accumulated Depreciation & Amortization value was $4.2 million (recorded in 2024), while the average stood at $5.8 million.
- Per our database at Business Quant, Arrowhead Pharmaceuticals' Accumulated Depreciation & Amortization changed by 0.0% in 2023 and then skyrocketed by 8636.36% in 2024.
- Arrowhead Pharmaceuticals' Accumulated Depreciation & Amortization (Quarter) stood at $2.1 million in 2021, then increased by 9.52% to $2.3 million in 2022, then surged by 65.22% to $3.8 million in 2023, then increased by 26.32% to $4.8 million in 2024, then increased by 25.0% to $6.0 million in 2025.
- Its Accumulated Depreciation & Amortization was $6.0 million in Q4 2025, compared to $22.2 million in Q3 2025 and $5.8 million in Q2 2025.